To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older

This study has been terminated.
(The study was terminated due to poor recruitment (after enrolling 62 of planned 300 patients in 20 months).)
Sponsor:
Collaborator:
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
Information provided by (Responsible Party):
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov Identifier:
NCT00082095
First received: April 29, 2004
Last updated: August 9, 2012
Last verified: August 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: December 2005
  Primary Completion Date: December 2005 (Final data collection date for primary outcome measure)